Yes, the FDA did just slap down PTC’s Duchenne MD drug for the third time

What­ev­er last shred of hope re­mained that PTC could turn things around and win a mir­a­cle ap­proval at the FDA for their Duchenne mus­cu­lar dy­s­tro­phy drug ataluren end­ed with a terse state­ment Wednes­day morn­ing not­ing that the agency has re­ject­ed their mar­ket­ing ap­pli­ca­tion.

Ac­cord­ing to PTC, the FDA has de­mand­ed more da­ta from a new clin­i­cal study, along with some CMC in­put along with ad­di­tion­al in­fo that the biotech says it is in the process of pro­vid­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER